
Bio-Techne rose 23.8% from $58.73 to $72.70, ahead of the S&P 500's +9.7%. Its worst day was May 6 (−16.4%), and its low came May 15 at $43.22.
Nov 20, 2025 – Nov 19, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $0.46 beat the $0.40 estimate on $295.9M revenue (est. $291.1M).
+6.3% · S&P 500 −0.5%
Bio-Techne shares fell 10.9%, while the S&P 500 fell 0.4%.
Story events cover the past 12 months · Times ET
−10.9% · S&P 500 −0.4%
EPS of $0.53 beat the $0.52 estimate on $311.4M revenue (est. $316.6M).
−16.4%, the year's worst day · S&P 500 +1.4%
Bio-Techne closed at its lowest level of the year, 26.4% below where the year started.
−3.4% · S&P 500 −1.2%
Bio-Techne shares rose 20.1%, while the S&P 500 rose 0.1%.
+20.1%, the year's best day, on 52M shares, the year's heaviest volume · S&P 500 +0.1%
EPS of $0.52 beat the $0.51 estimate on $321.2M revenue (est. $315.1M).
+0.1% · S&P 500 +0.3%
EPS of $0.44 beat the $0.44 estimate on $299.7M revenue (est. $292.5M).
+0.1% · S&P 500 +2.4%
Where it ended: a close of $72.70 on Nov 19, 2026. Up next: Q2 2027 earnings on Feb 3, 2027 (EPS est. $0.46, revenue est. $308.0M).
As of the Nov 19, 2026 close
Replay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for TECH and SPY from Benzinga historical bars. Not investment advice.